Jacob Stephen Thomas, MD, discussed the efficacy of first-line ipatasertib plus pembrolizumab in patients with recurrent or metastatic HNSCC.
Jacob Stephen Thomas, MD
Advertisement
Jacob Thomas, MD, is an assistant professor of clinical medicine and service chief of LAC+USC Oncology at Keck School of Medicine of the University of Southern California.
Articles by Jacob Stephen Thomas, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Generic Enzalutamide Tablets Granted Tentative FDA Approval for Prostate Cancer
2
The OncFive: Top Oncology Articles for the Week of 6/21
3
T-DXd Plus Pertuzumab Sets New Treatment and Research Standards in HER2+ Breast Cancer
4
Five Under 5: Top Oncology Videos for the Week of 6/21
5